FrancophonIA/ELRC3.0 huggingface dataset:
English: Updated advice on use of high-dose ibuprofen
Maltese: Aktar dwar il-proċedura
English: Reviews carried out in 2005, 2006, and 2012 confirmed that NSAIDs as a class are associated with a small increase in the risk of arterial thromboembolic events (blood clots in the arteries) especially in patients with underlying heart or circulatory conditions or with certain cardiovascular risk factors, and particularly if used at high doses.
Maltese: Reviżjonijiet imwettqin fl-2005, 2006, u 2012 ikkonfermaw lill-NSAIDs bħala klassi assoċjata ma' żieda żgħira fir-riskju ta' avvenimenti arterjali tromboemboliċi (emboli tad-demm fl-arterji) speċjalment f'pazjenti b'kundizzjonijiet tal-qalb jew taċ-ċirkolazzjoni eżistenti jew b'ċerti fatturi ta' riskju kardjovaskulari, u b'mod partikolari jekk jintużaw f'dożi għoljin.
English: Ibuprofen and dexibuprofen medicines have been authorised in the EU through national approval procedures and have been available for many years under a wide range of trade names.
Maltese: Il-mediċini li fihom ibuprofen u dexibuprofen ġew awtorizzati fl-UE permezz ta' proċeduri ta' approvazzjoni nazzjonali u ilhom disponibbli għal diversi snin taħt firxa wiesgħa ta' ismijiet kummerċjali.
English: Review confirms small cardiovascular risk with daily doses at or above 2,400 mg
Maltese: Ir-reviżjoni tikkonferma riskju kardjovaskulari żgħir b'dożi ta' kuljum ta' 2,400 mg jew aktar
English: The updated advice on the cardiovascular risk of high-dose ibuprofen will be included in the product information of ibuprofen medicines, along with information on the interaction between ibuprofen and aspirin.
Maltese: Il-parir aġġornat dwar ir-riskju kardjovaskulari ta' ibuprofen f'dożi għoljin ser jiġi inkluż fl-informazzjoni tal-prodott tal-mediċini li fihom ibuprofen, flimkien mal-informazzjoni dwar l-interazzjoni bejn ibuprofen u l-aspirina.
English: It works by blocking an enzyme called cyclooxygenase, which produces prostaglandins, substances that are involved in inflammation and pain.
Maltese: Huwa jaħdem billi jimblokka enzima msejħa cyclo-oxygenase, li tipproduċi l-prostaglandini, sustanzi li huma involuti flinfjammazzjoni u l-uġigħ.
English: It followed concerns that high doses of ibuprofen could have a similar cardiovascular risk to that of COX-2 inhibitors and diclofenac.
Maltese: Din segwiet tħassib li dożi għoljin ta' ibuprofen jista' jkollhom riskju kardjovaskulari simili għal dak ta' inibituri COX-2 u diclofenac.
English: Laboratory studies have shown that ibuprofen reduces the blood-thinning effects of aspirin.
Maltese: L-istudji fillaboratorju wrew li ibuprofen inaqqas l-effetti ta' traqqiq tad-demm tal-aspirina.
English: The review clarifies that the risk with highdose ibuprofen is similar to the risk seen with some other non-steroidal anti-inflammatory drugs (NSAIDs), including COX-2 inhibitors and diclofenac.
Maltese: Ir-reviżjoni tiċċara li r-riskju b'ibuprofen f'dożi għoljin huwa simili għar-riskju osservat b'xi mediċiniantinfjammatorji nonsterojdali (NSAIDs) oħra, inkluż inibituri COX-2 u diclofenac.
English: No clinically relevant effect is considered to be likely for occasional ibuprofen use.
Maltese: L-ebda effett klinikament rilevanti mhuwa kkunsidrat probabbli għall-użu okkażjonali ta' ibuprofen.
English: • An EU-wide review of ibuprofen has confirmed that there is a small risk of heart attacks and strokes in patients taking high doses of the medicine (at or above 2,400 mg per day).
Maltese: • Reviżjoni mifruxa madwar l-UE ta' ibuprofen ikkonfermat li hemm riskju żgħir ta' attakki tal-qalb u puplesiji f'pazjenti li jieħdu dożi għoljin tal-mediċina (2,400 mg kuljum jew aktar).
English: • The effect of duration of ibuprofen treatment on cardiovascular risk is uncertain.
Maltese: • L-effett tad-durata tal-kura b'ibuprofen fuq ir-riskju kardjovaskulari mhuwiex ċert.
English: • Patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus and smoking) should only be treated with high-dose ibuprofen after careful consideration.
Maltese: • Pazjenti b'fatturi ta' riskju għal avvenimenti kardjovaskulari (eż. pressjoni għolja, iperlipidemija, dijabete mellitus u tipjip) għandhom jirċievu kura b'ibuprofen f'dożi għoljin biss wara kunsiderazzjoni bir-reqqa.
English: For diclofenac, the risk was estimated at about 3 extra cases of heart attack in every 1,000 patients taking diclofenac for a year.
Maltese: Għal diclofenac, ir-riskju kien stmat f'madwar 3 każijiet aktar ta' attakk tal-qalb f'kull 1,000 pazjent li jieħdu diclofenac għal sena.
English: • Although no specific data about the cardiovascular risk with dexibuprofen are available, a similar cardiovascular risk to that with high-dose of ibuprofen is expected when dexibuprofen is used at equipotent doses (at or above 1,200 mg per day).
Maltese: • Għalkemm l-ebda dejta speċifika dwar ir-riskju kardjovaskulari mhija disponibbli b'dexibuprofen, riskju kardjovaskulari bħal dak b'doża għolja ta' ibuprofen huwa mistenni meta dexibuprofen jintuża f'dożi ekwipotenti (f'1,200 mg jew aktar kuljum).
English: This follows a review carried out by EMA's Pharmacovigilance Risk Assessment Committee (PRAC), which confirmed a small increased risk of cardiovascular problems, such as heart attacks and strokes, in patients taking high doses of ibuprofen (at or above 2,400 mg per day).
Maltese: Dan isegwi reviżjoni li saret mill-Kumitat tal-Evalwazzjoni tar-Riskju fil-qasam tal-Farmakoviġilanza (PRAC) tal-EMA, li kkonfermat żieda żgħira fir-riskju ta' problemi kardjovaskulari, bħal attakki tal-qalb u puplesiji, f'pazjenti li kienu qegħdin jieħdu dożi għoljin ta' ibuprofen (2,400 mg kuljum jew aktar).
English: • High doses of ibuprofen should be avoided in patients with cardiovascular conditions (e.g. uncontrolled hypertension, congestive heart failure (NYHA class II-III), established ischaemic heart disease, peripheral arterial disease and cerebrovascular disease).
Maltese: • Dożi għoljin ta' ibuprofen għandhom jiġu evitati f'pazjenti b'kundizzjonijiet kardjovaskulari (eż. pressjoni għolja mhux ikkontrollata, insuffiċjenza tal-qalb konġestiva (NYHA klassi
English: As ibuprofen medicines are all authorised nationally, the PRAC recommendations were forwarded to the Co-ordination Group for Mutual Recognition and Decentralised ProceduresHuman (CMDh), which adopted a final position.
Maltese: Peress li mediċini li fihom ibuprofen huma kollha awtorizzati fuq livell nazzjonali, ir-rakkomandazzjonijiet tal-PRAC intbagħtu lill-Grupp ta' Koordinazzjoni għal Proċedura tar-Rikonoxximent Reċiproku u l-Proċedura Deċentralizzata - Bniedem (CMDh), li adotta pożizzjoni finali.
English: No increase in cardiovascular risk is seen with ibuprofen at doses of up to 1,200 mg per day, which is the highest dose generally used for over-the-counter (OTC) preparations taken by mouth in the European Union (EU).
Maltese: Mhuwa osservat ebda riskju kardjovaskulari b'ibuprofen f'dożi sa 1,200 mg kuljum, li hija l-ogħla doża li s-soltu tintuża għal preparazzjonijiet li tixtrihom mingħajr riċetta (OTC) li jittieħdu mill-ħalq fl-Unjoni Ewropea (UE).
English: Ibuprofen is a painkiller and anti-inflammatory medicine that belongs to the class of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).
Maltese: Ibuprufen huwa mediċina għal kontra l-uġigħ u antinfjammatorja li tagħmel parti mill-klassi ta' mediċini msejħin mediċini antinfjammatorji nonsterojdali (NSAIDs).
English: To minimise the cardiovascular risk, high doses of ibuprofen (2,400 mg per day or higher) should be avoided in patients with serious underlying heart or circulatory conditions, such as heart failure, heart disease and circulatory problems or in those who have previously had a heart attack or stroke.
Maltese: Biex jitnaqqas ir-riskju kardjovaskulari, għandhom jiġu evitati dożi għoljin ta' ibuprofen (2,400 mg kuljum jew aktar) f'pazjenti b'kundizzjonijiet tal-qalb jew taċ-ċirkolazzjoni serji eżistenti, bħal insuffiċjenza tal-qalb u problemi fiċ-ċirkolazzjoni jew f'dawk li fil-passat kellhom attakk tal-qalb jew puplesija.
English: This latest review considered accumulated evidence which clarifies the cardiovascular risk related to ibuprofen taken at high doses and the interaction between ibuprofen at any dose and aspirin.
Maltese: Ir-reviżjoni tat ħarsa wkoll lejn id-dejta dwar l-interazzjoni bejn ibuprofen u l-aspirina f'dożi baxxi, meta din tal-aħħar tittieħed biex jitnaqqas ir-riskju ta' attakki tal-qalb u puplesiji.
English: No risk has been seen with ibuprofen at doses up to 1,200 mg per day, which is the highest dose usually taken by the majority of patients.
Maltese: Ma ġie osservat l-ebda riskju b'ibuprofen f'dożi sa 1,200 mg kuljum, li hija l-ogħla doża li ġeneralment tittieħed mill-maġġoranza tal-pazjenti.
English: The CMDh1 has endorsed by consensus updated advice on the use of high-dose ibuprofen.
Maltese: Is-CMDh1 approva b'kunsens parir aġġornat dwar l-użu ta' ibuprofen f'dożi għoljin.
English: The review was conducted by the Pharmacovigilance Risk Assessment Committee (PRAC), the Committee responsible for the evaluation of safety issues for human medicines, which made a set of recommendations.
Maltese: Ir-reviżjoni saret mill-Kumitat tal-Evalwazzjoni tar-Riskju fil-qasam tal-Farmakoviġilanza (PRAC), ilKumitat responsabbli għall-evalwazzjoni ta' kwistjonijiet tas-sigurtà għall-mediċini tal-bniedem, li għamel sett ta' rakkomandazzjonijiet.
English: Nimvastid is a ‘generic medicine'.
Maltese: Nimvastid huwa ‘mediċina ġenerika'.
English: It is available as capsules (yellow: 1.5 mg, orange: 3 mg, brownish red: 4.5 mg, and brownish red and orange: 6 mg) and as white orodispersible tablets (1.5 mg, 3 mg, 4.5 mg, and 6 mg).
Maltese: Huwa disponibbli f'forma ta' kapsuli (sofor: 1.5 mg; oranġjo: 3 mg; ħomor fil-kannella: 4.5 mg; ħomor fil-kannella u oranġjo: 6 mg) u bħala pilloli bojod orodispersibbli (1.5 mg, 3 mg, 4.5 mg, u 6 mg).
English: This summary was last updated in 05-2009.
Maltese: Is-sommarju ġie aġġornat l-aħħar fi: 05-2009.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) NIMVASTID EPAR summary for the public
Maltese: RAPPORT PUBBLIKU EWROPEW TA' VALUTAZZJONI (EPAR) NIMVASTID Sommarju tal-EPAR għall-pubbliku
English: The European Commission granted a marketing authorisation valid throughout the European Union for Nimvastid to KRKA,d.d., Novo mesto on 11 May 2009.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Nimvastid lil KRKA,d.d., Novo mesto fi 11 ta'Mejju 2009.
English: Nimvastid is a medicine that contains the active substance rivastigmine.
Maltese: Nimvastid huwa mediċina li fiha s-sustanza attiva rivastigmina.
English: The starting dose for Nimvastid is 1.5 mg twice a day.
Maltese: Id-doża inizjali ta' Nimvastid hija 1.5 mg darbtejn kuljum.
English: The active substance in Nimvastid, rivastigmine, is an antidementia medicine.
Maltese: Is-sustanza attiva f'Nimvastid, rivastigmina, hija mediċina kontra d-dimenzja.
English: What are the benefit and risk of Nimvastid?
Maltese: X'inhu l-benefiċċju u r-riskju ta' Nimvastid?
English: How has Nimvastid been studied?
Maltese: Kif ġie studjat Nimvastid?
English: Because Nimvastid is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine (this means that the two medicines produce the same levels of the active substance in the body).
Maltese: Minħabba li Nimvastid huwa mediċina ġenerika, l-istudji ġew limitati għal testijiet biex jiġi determinat li huwa bijoekwivalenti għall-mediċina ta' referenza (jiġifieri li ż-żewġ mediċini jipproduċu l-istess livelli ta' sustanza attiva fil-ġisem).
English: Rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase.
Maltese: Ir-rivastigmina taħdem billi timblokka lenzimi li jkissru l-aċetilkolina: aċetilkolinesterażi (acetylcholinesterase) u butirilkolinesterażi (butyrylcholinesterase).
English: What is Nimvastid?
Maltese: X'inhu Nimvastid?
English: For more information on generic medicines, see the question-and-answer document here.
Maltese: Għal aktar informazzjoni dwar ilmediċini ġeneriċi, ara d-dokument mistoqsija-u-tweġiba hawn.
English: Nimvastid is used for the treatment of patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Maltese: Nimvastid jintuża fit-trattament ta' pazjenti b'dimenzja tat-tip Alzheimer minn ħafifa għal moderatament gravi li hija tip ta' disturb tal-moħħ progressiv li jolqot gradwalment il-memorja, labilità intellettwali u l-imġiba.
English: This means that Nimvastid is similar to a ‘reference medicine' already authorised in the European Union (EU) called Exelon.
Maltese: Dan ifisser li Nimvastid huwa simili għal ‘mediċina ta' referenza' diġà awtorizzata fl-Unjoni Ewropea (UE) bl-isem Exelon.
English: In patients who tolerate this dose, it can be increased in 1.5-mg steps no more frequently than every two weeks, to a regular dose of 3 to 6 mg twice a day.
Maltese: Jekk din id-doża tiġi tollerata sew, tista' tiżdied b'1.5 mg kull doża waħda, iżda mhux iktar frekwenti minn ġimagħtejn bejn żieda u oħra, sakemm tintlaħaq doża regolari ta' 3-6 mg darbtejn kuljum.
English: Because Nimvastid is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Maltese: Billi Nimvastid huwa mediċina ġenerika u huwa bijoekwivalenti għall-mediċina ta' referenza, ilbenefiċċji u r-riskji jitqiesu li kienu l-istess bħal dawk tal-mediċina ta' referenza.
English: It is also used to treat mild to moderately severe dementia in patients with Parkinson's disease.
Maltese: Jintuża wkoll għat-trattament tad-dimenzja minn ħafifa għal moderatament gravi f'pazjenti bil-marda ta' Parkinson.
English: The full EPAR for Nimvastid can be found here.
Maltese: Għaliex ġie approvat Nimvastid?
English: Other information about Nimvastid:
Maltese: Tagħrif ieħor dwar Nimvastid:
English: By blocking these enzymes, Nimvastid allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer's dementia and dementia due to Parkinson's disease.
Maltese: Billi jimblokka dawn l-enzimi, Nimvastid jippermetti żieda fil-livelli ta' aċetilkolina fil-moħħ u b'dan il-mod jgħin biex inaqqas is-sintomi tad-dimenzja tat-tip Alzheimer u tad-dimenzja dovuta għall-marda ta' Parkinson.
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Nimvastid has been shown to have comparable quality and to be bioequivalent to Exelon.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) ikkonkluda li, b'mod konformi mar-rekwiżiti tal-UE, Nimvastid wera li għandu kwalità komparabbli ma' u huwa bijoekwivlenti għal Exelon.
English: How is Nimvastid used?
Maltese: Kif jaħdem Nimvastid?
English: Nimvastid orodispersible tablets should be placed on the tongue, where they disintegrate quickly in the saliva before being swallowed.
Maltese: Il-Kumitat irrakkomanda li Nimvastid jingħata awtorizzazzjoni għat-tqegħid fissuq.
English: The full EPAR for Zevalin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The active substance in Zevalin, ibritumomab, is a monoclonal antibody.
Maltese: Is-sustanza attiva f'Zevalin, l-ibritumomab, hija antikorp monoklonali.
English: Zevalin must be given as a slow infusion lasting 10 minutes.
Maltese: Zevalin jingħata permezz ta' infużjoni intravenuża bil-mod tul 10 minuti.
English: This summary was last updated in 09-2011.
Maltese: Dan is-sommarju kien aġġornat l-aħħar f'09-2011.
English: EPAR summary for the public ibritumomab tiuxetan
Maltese: Sommarju tal-EPAR għall-pubbliku ibritumomab tiuxetan
English: When Zevalin is radiolabelled, the radioactive element yttrium 90 (90Y) is attached to ibritumomab.
Maltese: Meta Zevalin ikun radjummarkat, l-element radjuattiv ittrju 90 (90Y) jintrabat mal-ibritumomab.
English: This is a summary of the European public assessment report (EPAR) for Zevalin.
Maltese: Dan id-dokument huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Zevalin.
English: The most common side effects with Zevalin (seen in more than 1 patient in 10) are anaemia (low red blood cell counts), leucocytopenia and neutropenia (low white blood cell counts), thrombocytopenia (low blood platelet counts), asthenia (weakness), pyrexia (fever), rigors (stiffness) and nausea (feeling sick).
Maltese: L-effetti sekondarji l-aktar komuni bil-kura b'Zevalin (li dehru f'aktar minn pazjent 1 minn 10) huma anemija (għadd baxx ta' ċelluli tad-demm ħomor), lewkoċitopenija u newtropenija (għadd baxx ta' ċelluli tad-demm bojod), tromboċitopenija (għadd baxx ta' platelets), astenija (debbulizza), piressija (deni), riġidità (ebusija) u nawżja (dardir).
English: The CHMP decided that Zevalin's benefits are greater than its risks as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma and for the treatment of adult patients with rituximab relapsed or refractory CD20-positive follicular B cell non Hodgkin's lymphoma.
Maltese: Is-CHMP iddeċieda li l-benefiċċji ta' Zevalin huma ogħla mir-riskji tiegħu bħala terapija ta' konsolidament wara induzzjoni ta' remissjoni f'pazjenti mhux ittrattati qabel li jbatu mil- linfoma follikulari u fit-trattament ta' pazjenti adulti li jbatu mil-linfoma mhux ta' Hodgkin follikulari b'ċelluli B CD20 pożittiv, b'attakki reċidivi jew refrattarji għat-trattament bir-rituximab.
English: Why has Zevalin been approved?
Maltese: Għaliex ġie approvat Zevalin?
English: In patients who were not responding to other treatments or whose disease had come back after previous treatment, Zevalin was more effective than rituximab: 80% of the patients receiving radiolabelled Zevalin responded, compared with 56% of the patients receiving rituximab.
Maltese: Fil-pazjenti li ma kinux qegħdin jirrispondu għat-trattamenti l-oħrajn jew li reġgħet ħarġitilhom ilmarda wara trattament preċedenti, irriżulta li Zevalin kien aktar effikaċi mir-rituximab: irrisponda perċentwal ta' 80% tal-pazjenti ttrattati b'Zevalin radjummarkat, apparagun ma' 56% li kienu qed jingħataw ir-rituximab.
English: Zevalin is used in the following groups of patients:
Maltese: Zevalin jintuża f‘dawn il-gruppi ta' pazjenti:
English: For consolidation therapy, Zevalin has been studied in one main study involving 414 patients who had achieved a partial or complete remission during induction treatment for non Hodgkin's lymphoma.
Maltese: Għat-terapija ta' konsolidament, Zevalin ġie eżaminat fi studju ewlieni wieħed li involva 414-il pazjent li kisbu remissjoni parzjali jew totali matul it-trattament ta' induzzjoni għal-linfoma mhux ta' Hodgkin.
English: What is Zevalin?
Maltese: X'inhu Zevalin?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Zevalin on 16 January 2004.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq għal Zevalin valida fl-Unjoni Ewropea kollha fis-16 ta' Jannar 2004.
English: Ibritumomab has been designed to target an antigen, CD20, which is present on the surface of all B lymphocytes.
Maltese: L-ibritumomab inħolqot biex tintrabat mal-antiġene, CD20, li jkun preżenti fuq wiċċ il-linfoċiti B kollha.
English: How has Zevalin been studied?
Maltese: Kif ġie studjat Zevalin?
English: Zevalin has also been studied in a total of 306 patients with non Hodgkin's lymphoma who were not responding to other treatments or whose disease had come back after previous treatment.
Maltese: Zevalin ġie studjat ukoll fuq total ta' 306 pazjenti bil-linfoma mhux ta' Hodgkin li ma kinux qegħdin jirrispondu għal trattamenti oħrajn jew li kienu rkadew wara trattament preċedenti.
English: The main study compared the effectiveness of Zevalin with that of rituximab in 143 patients.
Maltese: L-istudju ewlieni qabbel l-effikaċja ta' Zevalin ma' dik tar-rituximab f'143 pazjent.
English: Zevalin is radiolabelled by mixing it with a solution of radioactive yttrium (90Y) chloride.
Maltese: Zevalin jiġi radjummarkat billi jitħallat ma' soluzzjoni tal-klorur tal-ittrju (90Y) radjuattiv.
English: The doctor who prescribes it must ensure that the risks linked to the exposure to the radioactivity are lower than the risks from the disease itself.
Maltese: Zevalin radjummarkat jipproduċi r-radjuattività u jista' jwassal għal riskju ta' kanċer jew difetti ereditarji.
English: As the company had supplied the additional information requested, the ‘exceptional circumstances' ended on 22 May 2008.
Maltese: Billi l-kumpanija pprovdiet it-tagħrif addizzjonali mitlub, iċ‘ċirkostanzi eċċezzjonali' ntemmu fit-22 ta' Mejju 2008.
English: Zevalin is a kit for the preparation of a ‘radiolabelled' infusion (drip into a vein) of the active substance ibritumomab tiuxetan.
Maltese: Zevalin huwa kitt għall-preparazzjoni għall-infużjoni (drip fil-vina) radjummarkata (radiolabelled) tassustanza attiva ibritumomab tiuxetan.
English: What is the risk associated with Zevalin?
Maltese: X'inhu r-riskju assoċjat ma' Zevalin?
English: In an additional study, 57 patients with follicular lymphoma who had been previously treated and were not responding to rituximab received Zevalin.
Maltese: Fi studju addizzjonali, 57 pazjent li kienu jbatu mil-linfoma follikulari, li kienu ġew ittrattati qabel u ma kinux qegħdin jirrispondu għarrituximab, ingħataw Zevalin.
English: This is a cancer of the lymph tissue (part of the immune system) that affects a type of white blood cell called B lymphocytes, or B cells.
Maltese: Dan huwa tip ta' kanċer tat-tessut linfatiku (parti mis-sistema immunitarja) li jolqot tip ta' ċelluli tad-demm bojod imsejħa ‘linfoċiti B' jew ‘ċelluli B'.
English: For the full list of all side effects reported with Zevalin, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji rrappurtati b'Zevalin, ara l-fuljett ta' tagħrif.
English: This is followed, seven to nine days later, by a second infusion of rituximab and an injection of radiolabelled Zevalin.
Maltese: Wara bejn 7 u 9 ijiem, tingħata t-tieni infużjoni tar-rituximab u linjezzjoni ta' Zevalin radjummarkat.
English: How does Zevalin work?
Maltese: Għal xiex jintuża Zevalin?
English: ‘consolidation therapy' to improve the remission; patients in whom rituximab (another treatment for non Hodgkin's lymphoma) is no longer effective or whose disease has come back after rituximab treatment.
Maltese: • pazjenti li għalihom ir-rituximab (trattament ieħor għal-linfoma mhux ta' Hodgkin) ma jkunx għadu effikaċi jew li terġa' toħorġilhom il-marda wara trattament bir-rituximab.
English: Zevalin should not be used in people who may be hypersensitive (allergic) to ibritumomab, yttrium chloride, mouse proteins or any of the other ingredients.
Maltese: Zevalin ma għandux jingħata lil pazjenti li jistgħu jkunu ipersensittivi (allerġiċi) għall-ibritumomab, għall-klorur tal-ittrju , għall-proteini tal-ġurdien jew għal kwalunkwe ingredjent ieħor tiegħu.
English: Other information about Zevalin
Maltese: Kif jintuża Zevalin?
English: A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found in certain cells in the body.
Maltese: Antikorp monoklonali hu tip ta' antikorp (tip ta' proteina) maħsub biex jagħraf u jintrabat ma' struttura speċifika (magħrufa bħala antiġene) li jinstab fuq ċerti ċelloli fil-ġisem.
English: Patients receiving radiolabelled Zevalin survived for an average of 37 months until their disease got worse, compared with 14 months in those who did not receive any further treatment.
Maltese: Il-pazjenti ttrattati b'Zevalin radjummarkat għexu għal perjodu medju ta' 37 xahar qabel ma l-marda tagħhom aggravat, apparagun mal-14-il xahar ta' dawk li ma ngħataw l-ebda trattament ulterjuri.